Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify ...
29m
Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue - - Reports positive feedback from the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback